A Randomized Double-Blind Placebo-Controlled Study in Cat-Allergic Patients with Allergic Rhinitis Who Live with a Cat to Assess the Efficacy and Safety of Anti-Fel d 1 Antibodies during Natural Cat Exposure in the Home

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Allergic Rhinitis
  • Age: Between 12 - 100 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Weight must be equal to or greater than 40 kg at the time of screening
    2. Documented or patient reported history (for at least 2 years) of symptomatic cat allergen triggered allergic rhinitis with or without conjunctivitis and with or without asthma
    3. At least 1 generally healthy cat (that is unlikely to die during the study) living in the home resulting in regular exposure
    4. Willing and able to comply with clinic visits and study-related procedures
    5. Provide informed consent
    6. Able to understand and complete study-related questionnaires

You may not be eligible for this study if the following are true:

    1. History of significant multiple and/or severe allergies
    2. Received REGN1908-1909 in a prior REGN1908-1909 clinical trial
    3. Active lung disease other than asthma
    4. Treatment with an investigational drug within 2 months or within 5 half-lives
    5. Persistent chronic or recurring acute infection requiring treatment with antibiotics, antivirals, or antifungals, or any untreated respiratory infections within 4 weeks prior to screening.
    6. Use of anti-IgE or other biological therapy (including but not limited to anti IL-5, anti IL-4) that interferes with type 2 disease within 6 months prior to screening visit 1
    7. Specific immunotherapy (SIT) with cat allergen or cat vaccine within 6 months prior to screening visit 1
    8. SIT with any allergen other than cat within 6 months prior to screening visit 1
    9. Patients who have recently started (within 12 weeks prior to screening visit 1) and plan to continue or plan to start their cat(s) on an anti-allergen cat food (eg, Purina Pro Plan® LiveClear) or other anti-allergen treatment during the study
    10. History of life-threatening asthma
    11. History of intensive care hospitalization for asthma within past 2 years
    12. History of intolerance to systemic or topical corticosteroids or antihistamines, or drug treatment excipient
    13. History of nasal polyps
    14. History of drug or alcohol abuse within a year prior to screening
    15. Any malignancy within the past 5 years
    16. Pregnant or breastfeeding women
    17. Women of childbearing potential (WOCBP)* who are unwilling to practice highly effective contraception prior to the initial dose/start of the first treatment, during the study, and for at least 24 weeks after the last dose



If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.